850364-08-8

Basic information

• Product Name: 4-(BENZYLOXY)-1H-INDAZOLE
• Synonyms: 4-(BENZYLOXY)-1H-INDAZOLE;4-(Phenylmethoxy)-1H-indazole;1H-Indazole, 4-(phenylMethoxy)-
• CAS NO: 850364-08-8
• Molecular Formula: C₁₄H₁₂N₂O
• Molecular Weight: 224.25788
• Product Categories: Indazole
• Mol File: 850364-08-8.mol
• Article Data: 4

Chemical Properties

• Melting Point: 118-123℃ (heptane )
• Boiling Point: 422.4 °C at 760 mmHg
• Flash Point: 152.5 °C
• Appearance: /
• Density: 1.247 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-(BENZYLOXY)-1H-INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(BENZYLOXY)-1H-INDAZOLE(850364-08-8)
• EPA Substance Registry System: 4-(BENZYLOXY)-1H-INDAZOLE(850364-08-8)

Safety Data

• Hazardous Substances Data: 850364-08-8(Hazardous Substances Data)

Usage

Description

4-(Benzyloxy)-1H-indazole is an organic compound that serves as a key intermediate in the synthesis of various pharmaceuticals and bioactive molecules. It is characterized by the presence of a benzyloxy group attached to the indazole ring, which contributes to its unique chemical properties and reactivity.

Uses

Used in Pharmaceutical Synthesis:
4-(Benzyloxy)-1H-indazole is used as a reactant in the synthesis of AG035029, a PPARy agonist. 4-(BENZYLOXY)-1H-INDAZOLE plays a crucial role in the development of drugs targeting peroxisome proliferator-activated receptors, which are involved in various biological processes, including glucose metabolism, inflammation, and cell differentiation.
In the pharmaceutical industry, 4-(Benzyloxy)-1H-indazole is used as a building block for the creation of novel therapeutic agents with potential applications in treating a range of diseases, such as diabetes, obesity, and inflammatory disorders. Its unique structure allows for the design of molecules with improved pharmacokinetic and pharmacodynamic properties, enhancing their efficacy and safety profiles.

Upstream product

• 20876-37-3 2-benzyloxy-6-nitrotoluene 
• 65361-82-2 3-benzyloxy-2-methyl-phenylamine 
• 81382-45-8 4-hydroxyindazole 
• 100-39-0 benzyl bromide 
• 65361-84-4 1-acetyl-4-benzyloxy-1H-indazole 
• 368-21-8 2-fluorophenyl phenylmethyl ether 

Downstream Products

• 1056265-48-5 1-[4-(methyloxy)phenyl]-4-[(phenylmethyl)oxy]-1H-indazole 
• 1056265-55-4 1-[3-chloro-4-(methyloxy)phenyl]-4-[(phenylmethyl)oxy]-1H-indazole 
• 1056265-71-4 1-{3,5-difluoro-4-[(phenylmethyl)oxy]phenyl}-4-[(phenylmethyl)oxy]-1H-indazole 
• 1056265-63-4 1-[3-methyl-4-(methyloxy)phenyl]-4-[(phenylmethyl)oxy]-1H-indazole 
• 669077-49-0 AG₀₃₅₀₂₉ 
• 1056263-01-4 1-(3,5-difluoro-4-hydroxyphenyl)-1H-indazol-4-ol 
• 1056262-85-1 1-(3-chloro-4-hydroxyphenyl)-1H-indazol-4-ol 
• 1056261-59-6 1-(3-fluoro-4-hydroxyphenyl)-1H-indazol-4-ol 
• 1056262-93-1 1-(4-hydroxy-3-methylphenyl)-1H-indazol-4-ol 
• 1056262-77-1 1-(4-hydroxyphenyl)-1H-indazol-4-ol 

Relevant articles and documents

INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS

The present invention relates to novel indazole derivatives (I) having pharmacological activity, processes for their preparation, compositions containing them and uses of these compounds in the treatment of estrogen receptor beta mediated diseases.

NOVEL INDAZOLE DERIVATIVE

An object of the present invention is to create a novel indazole derivative useful as a drug and to find a novel pharmacological action of the derivative. The compound of the present invention is represented by the formula [I] and has an excellent Rho kinase inhibiting action. In the formula, a ring X is a benzene ring or a pyridine ring; R1 and R2 are H or alkyl; R3 and R4 are halogen, H, OH, alkoxy, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, aryloxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, carboxy, hydrocarbonyl, alkylcarbonyl, etc.; and R5 is halogen atom, H, OH, alkoxy, aryloxy, alkyl or aryl. Each group can be substituted.